1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • July 2014
  • 91 pages
  • GlobalData
Report ID: 2370540

Summary

Table of Contents

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Xarelto was approved in the EU for the prevention of non-valvular atrial fibrillation (AF)-related stroke and systemic embolism, and for the treatment of deep vein thrombosis (DVT). On July 1, 2011, Xarelto was approved in the US to reduce the risk of blood clots, DVT, and pulmonary embolism (PE) following hip or knee replacement surgery, and in November of the same year, it was approved for stroke prevention in patients with non-valvular AF.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Acute Coronary Syndrome - Pipeline Insight, 2017

  • $ 1250
  • Industry report
  • July 2017
  • by Delve Insight

DelveInsight’s, “ Acute Coronary Syndrome -Pipeline Insights, 2017”, report provides comprehensive insights about pipeline drugs across this Acute Coronary Syndrome. The key objective of the report ...

Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • February 2017
  • by GlobalData

Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017” provides an overview ...

Antithrombotic Drugs - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • February 2017
  • by Stratistics MRC

According to Stratistics MRC, the Global Antithrombotic Drugs market is accounted for $XX million in 2016 and is expected to reach $XX million by 2022 growing at a CAGR of XX% from 2016 to 2022. Rising ...


Download Unlimited Documents from Trusted Public Sources

Cardiovascular Disease Statistics in the UK

  • July 2017
    11 pages
  • Cardiovascular ...  

  • United Kingdom  

View report >

Hospital Industry in Europe

  • July 2017
    10 pages
  • Hospital  

    Therapy  

  • Europe  

    United States  

View report >

Renal Disease Statistics in the US

  • July 2017
    14 pages
  • Renal Disease  

    Diabetes  

  • United States  

View report >

Hospital Industry

1 month ago

Related Market Segments :

Acute Coronary Syndrome

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.